Vyne selects development candidate from BD2-selective BET inhibitor program for immuno-inflammatory conditions

May 2, 2023

Vyne Therapeutics Inc. has selected a development candidate, VYN-202, for its oral BD2-selective bromodomain and extra-terminal (BET) inhibitor program for the treatment of immuno-inflammatory conditions.

BioWorld Science Immune Inflammatory

Today's news in brief

BioWorld

BioWorld briefs for April 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 22, 2025.

Three lines of white dice with people icons, red dice with scissors icons

Biopharma restructurings reflect strategy of short-term pain for long-term gains

BioWorld

Ongoing restructurings in the biopharma sector show common themes of cost-cutting, clinical failures and shifting strategic priorities. Companies are increasingly...

Field Medical harvests $40M for PFA system

BioWorld MedTech

Field Medical Inc. reaped $40 million in its series A fundraising via $20 million in new capital and conversion of $20 million in seed-round debt to support...

Roche cobas IMPACT: chip-based immunological multimarker assay

Roche follows other pharmas, committing $50B in US investment

BioWorld

Roche AG has become the latest pharmaceutical company to respond to the Trump administration’s threat to impose tariffs, saying it will invest $50 billion in drug...